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Positive and Negative Symptoms in Schizophrenia 
and the Dexa~ethas~ne Suppression Test 
Rajiv Tandon, Kenneth R. Silk, John F. Greden, Joann Goodson, 
M. Hariharan, James H. Meador-Woo~ff, and Ziad Kronfol 
Although the Dexamethasone Suppression Test 
(DST) was originally proposed as a specific 
marker for major depressive disorder (Carroll et 
al. 1981), several recent studies have reported 
high rates of DST nonsuppression in schizo- 
phrenic patients, ranging from 22% to 73%. 
DST nonsuppression in schizophrenia has been 
attributed to depressive symptomatology (Munro 
et al. 1983), negative symptomatology (Coppen 
et al. 1983; Shima et al. 1986), subtype differ- 
ences (Banki et al. 1984), episodic course, and 
good prognosis (Targum 1983). Investigations 
have so far yielded discrepant findings, prompt- 
ing at least one author (Myers 1984) to suggest 
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that DST nonsupp~ssion in schizophrenia is a 
random event. The present study was conducted 
to investigate the relationship of symptomatol- 
ogy (depressive, Positive, negative) and clinical 
phase to the DST response. 
The sample consisted of 20 consecutively hos- 
pitalized patients who were admitted to the In- 
patient Schizophrenic Program at the University 
of Michigan. All patients met DSM-III-R cri- 
teria (American Psychiatric Association 1987) 
and Research Diagnostic Criteria @DC) (Spitzer 
et al. 1978) for schizophrenia. Informed consent 
for participation in the study was duly obtained. 
Patients with organic brain disorder, somatic 
disease, or alcohol or other substance abuse in 
the preceding 6 months, or any of the medical 
exclusion criteria for a valid DST (Carroll et al. 
1981), were excluded. The sample consisted of 
I2 men and 8 women with a mean age of 28.7 
years (range 20-4.5) and a mean duration of 
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illness of 5.6 years (range 1-15 years). Patients 
were maintained in a drug-free state for 2 weeks, 
during which weight constancy was carefully 
monitored. A 1 -mg DST was performed at base- 
line (after patient had been medication-free for 
at least 2 weeks) and was repeated after about 
4 weeks of treatment with clinically determined 
doses of haloperidol, thiothixene, or thorazine 
singly, or in combination with 2-6 mg of tri- 
hexiphenidyl. The test was performed by admin- 
istration of 1 mg of dexamethasone in tablet 
form at 11:OO PM and collection of blood sam- 
pleS for analysis of cortisol levels at 4:00 PM 
and 1l:OO PM the next day. Cortisol levels were 
assayed by Murphy’s competitive protein-bind- 
ing method (Murphy 1967). Maximal postdex- 
amethasone cortisol levels of >5 &g/d1 were 
considered to be indicative of nonsuppression. 
Patients were rated (all by R.T.) on the Brief 
Psychiatric Rating Scale (BPRS) (Overall 1984), 
Scale for the Assessment of Negative Symptoms 
(SANS) (Andreasen 1982), and the 17-item 
Hamilton Rating Scale for Depression (HRSD) 
(Hamilton 1960) at baseline and after about 4 
weeks of neuroleptic treatment. Clinical ratings 
and the corresponding DST were performed 
within a day of each other. The rater was blind 
to all DST results. Global clinical assessment 
was done by the 18-item BPRS total score. Pos- 
itive symptoms were assessed by the sum of the 
following 7 BPRS items: conceptual disorgan- 
ization, mannerisms and posturing, hostility, 
suspiciousness, hallucinatory behavior, unusual 
thought content, and excitement. Negative 
symptoms were assessed by the SANS, with the 
sum of global scores being employed for anal- 
ysis. Depressive symptoms were assessed by the 
sum of the 17-item HRSD. Comparisons of de- 
mo~phics and rating scale scores between the 
initial (baseline) nonsuppressors and suppres- 
sors were made by the two-tailed Students t- 
test. 
Results 
Seven of the 20 patients were nonsuppressors 
at baseline. Baseline suppressors and nonsup- 
pressors are comp~d on various clinical and 
other parameters in Table 1. The two @oups 
did not differ with regard to age, sex distri- 
bution, or total duration of illness. Nonsup- 
pressors had a shorter duration of current psy- 
chotic exacerbation (from the time of reported 
onset of current exacerbation to the time of 
admission). The two groups did not differ with 
regard to baseline or posttreatment global se- 
verity, positive symptoms, or depressive 
symptoms. Initial DST nonsupp~ssion was 
associated with improvement in negative 
symptoms with treatment (SANSwtia - SAN- 
S posttreahnenO, improvement in global severity 
with treatment (assessed by change in BPRS), 
and showed a trend toward significant associ- 
ation with baseline negative symptoms. There 
was no association with change in positive or 
depressive symptoms. All seven initial non- 
suppressors had no~alized or become DST 
suppressors following neuroleptic treatment, 
whereas all initial suppressors remained sup- 
pressive. 
There was a significant correlation between 
baseline negative symptoms and maximal post- 
dexamethasone cortisol levels (r = 0.59, n = 
20, p < 0.01). There was no significant rela- 
tionship between maximal postdexamethasone 
cortisol levels and positive symptoms, global 
severity, or depressive symptoms at baseline or 
4 weeks following neuroleptic treatment. In the 
posttreatment phase, the correlation between 
negative symptoms and postdexamethasone cor- 
tisol levels was also not significant (r = 0.13, 
n = 20, NS). 
Although all patients were drug-free for at 
least 2 weeks before the initial DST, Kraus et 
al. (1988) suggest that withdrawal of neuro- 
leptics and ~tip~~nsoni~ agents may pro- 
duce DST nonsuppression lasting up to 21 
days. Analysis of the data to examine this 
possibility revealed that 10 patients had been 
drug-free for more than 1 month prior to the 
initial DST; of these, 6 were DST nonsup- 
pressors at baseline. Only 1 of 10 patients dmg- 
free for less than a month was an initial non- 
suppressor. Thus, psychotropic withdrawal ef- 
fects did not account for the initial DST non- 
supp~ssion noted in our study. 
790 BIOL PSYCHIATRY 
1989;25:788-792 
Brief Report> 
Table 1. Comparison of Initial DST Suppressor and Nonsuppressor Groups 
Parameter 
Suppressors Nonsuppressors 
(n = 13) (n = 7) 
Age duration 
Illness (years) 
Current exacerbation (weeks) 



















28.5 -+ 6.3 
5.2 t 2.0 
21.4 t 21.2 
2.3 ” 0.89 
1.6 -t 0.46 
10.2 2 4.7 
7.0 f 3.2 
3.2 -+ 2.1 
22.7 f 5.4 
12.8 4 6.3 
9.9 2 5.3 
13.8 2 3.9 
9.3 -t 4.4 
4.5 2 2.1 
41.4 -t 14.9 
26.1 k 6.5 
21.3 ” 7.1 
29.2 -t 4.1 
6.3 2 4.2 
6.6 _t 4.2’ 
10.2 t 3.6’ 
1.8 2 0.91 
Il.4 + 4.0 
1.6 t 2.6 
3.8 + 2.9 
22.7 t 5.3 
11.1 i 5.0 
11.6 t 7.5 
16.1 t 2.8” 
1.7 2 2.9 
8.4 r 1.9’ 
51.7 k 10.2 
24.5 + 5.4 
27.2 t 6.2h 
All values are expressed as means t standard deviation. 
“p < 0.10. 
“p i 0.05. 
‘p < 0.01. 
Discussion 
Thirty-five percent of the schizophrenic patients 
in our sample were DST nonsuppressors at med- 
ication-free baseline (a figure intermediate be- 
tween the 0% to 73% rates reported in literature); 
however, 4 weeks after neuroleptic treatment, all 
20 patients in our study were DST suppressors. 
This finding is consistent with recent reports of 
DST nonsuppression in the acute phase of 
schizophrenic illness, with normalization fol- 
lowing resolution of acute symptoms (Baumgart- 
ner et al. 1986; MolIeret al. 1986; Wiket al. 1986; 
Holsboer-Trachsler et al. 1987). Our finding of 
an association between initial DST nonsuppres- 
sion and acuteness of current psychotic exacer- 
bation lends additional support to this linkage. 
Assessment at different clinical stages of schizo- 
phrenia and variable medication status may par- 
tially explain the discrepancies in rates of DST 
nonsuppression reported in schizophrenia; a lit- 
erature review reveals that investigations of med- 
ication-free schizophrenic patients with an acute 
exacerbation found higher rates of DST non- 
suppression than studies of neuroleptic-stabi- 
lized chronic schizophrenic patients. 
Initial DST nonsuppression was significantly 
associated with improvement in negative symp- 
toms with neuroleptic treatment and showed a 
trend toward association with baseline negative 
symptoms. Postdexamethasone cortisol levels 
were significantly correlated with negative 
symptoms at baseline, although this association 
was not observed after 4 weeks of neuroleptic 
treatment. Thus, the finding of an association be- 
tween negative symptoms and DST nonsuppres- 
sion at drug-free baseline was lost in the post- 
treatment phase. As with rates of DST 
nonsuppression, variable clinical phase and 
medication status may partially account for dis- 
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parate findings with regard to the relationship be- 
tween DST nonsuppression and negative symp- 
toms in schizophrenia. 
DST nonsup~ssion was associated with 
greater clinical improvement after 4 weeks of 
neuroleptic treatment, in agreement with reports 
that suggest that DST nonsuppression in schizo- 
phrenia predicts a better outcome of the index 
episode (Targum 1983). Acuteness of onset and 
good outcome are considered to be disting~sh- 
ing features of affective disorders. The associ- 
ation of DST nonsuppression with these clinical 
variables may be viewed as indicating that 
depression may be related to DST nonsuppres- 
sion in schizop~enia; however, no such asso- 
ciation was noted in our study. Based on the 
similarity between the behavioral profile pro- 
duced by cholinergic overdrive to the negative 
schizophrenic syndrome (Greden et al. 1988), 
response of negative symptoms to anticholin- 
ergic event (Tandon et al. 1988), sleep EEG, 
and other data (Tandon and Greden 1988a), cho- 
linergic hyperactivity has been proposed as a 
possible mechanism in the production of neg- 
ative schizophrenic symptoms. As cholinergic 
hyperactivity is associated with DST non- 
supp~ssion (Carroll et al. 1980), the ass~iation 
of DST nonsuppression with negative symptoms 
may provide support for the cholinergic excess 
hypothesis of negative symptoms (Tandon and 
Greden 1988b). Alternatively, DST non- 
suppression in the acute phase of the illness may 
represent a nonspecific response to stress. This 
would not, however, account for the relation- 
ship between DST nonsuppression and negative 
symptoms. 
Differences in clinical phase of assessment 
and medication status may explain the widely 
discrepant rates of DST nonsuppression and 
variable association of this finding with negative 
symptoms in schizophrenia. The precise mech- 
anism of DST nonsuppression in schizophrenia 
is unclear and remains to be evaluated. 
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Normal P300 in Acute Schizophrenics During a 
Continuous Performance Test 
Michael Wagner, Gabriele Kurtz, and Rolf R. Engel 
Introduction 
Evidence from many studies indicates that the 
vigilance deficit tapped by a visual continuous 
performance test (CPT) may be a promising vul- 
nerability marker of schizophrenia (Nuechter- 
lein 1985). A reduced P300 component of the 
cortical event-related potential (ERP) in schizo- 
phrenics has been reported almost consistently 
and is considered to be related to such atten- 
tional impairments (Pritchard 1986). So far, only 
Pass et al. (1980) have recorded ERPs of schizo- 
phrenics during the CPT. They also found a 
smaller P300 amplitude in acute psychotic pa- 
tients. We obtained contrasting results in a sim- 
ilar study. 
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schizophrenia (9 men) were studied. Their ages 
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